Reality

Quote

Anonymous

Guest
Cadence Pharmaceuticals lost $15.9 million, or 19 cents per share, in the third quarter ended Sept. 30. In the same quarter a year ago, Cadence lost $21.8 million, or 34 cents per share. (The per-share amounts are not comparable, because Cadence issued 21,800 shares in November 2011.)

Cadence reported revenue of $13.9 million for the quarter, compared with $3.5 million in the year-ago quarter. Cadence sells Ofirmev, an intravenous formulation of the painkiller acetaminophen.
 






Anonymous said:
Cadence Pharmaceuticals lost $15.9 million, or 19 cents per share, in the third quarter ended Sept. 30. In the same quarter a year ago, Cadence lost $21.8 million, or 34 cents per share. (The per-share amounts are not comparable, because Cadence issued 21,800 shares in November 2011.)
.
.
I'm tired of women bitching when guys fart. Farting around a woman is like listening to a radio permanently stuck on the wailing bitch station: "I CAN'T BELIEVE YOU FARTED." Yeah it's real hard to believe that guys have the ability to let out air from their colons, call Ripley.
.
.

Cadence reported revenue of $13.9 million for the quarter, compared with $3.5 million in the year-ago quarter. Cadence sells Ofirmev, an intravenous formulation of the painkiller acetaminophen.
Click to expand...
.
.i think it all is blue sky's and butterflies.
 






But wait, there's hope:

Theodore R. Schroeder

We’re seeing good strategic opportunities, I think as we’ve discussed before our business development appetitive actually falls into a range of potential transactions everything from a co-promotion, co-marketing agreements to product licensing to acquisition of products. So we have a variety of products in each of those categories where we’re advancing discussions, and there is some or more competitive than others, and I think that’s probably on the acquisitions in the licensing side, that’s probably a bit more competitive than the co-marketing type of arrangements would be, because I think folks tend to actually narrow down on their preferred partners fairly quickly in those scenarios.

so a lot to choose from doing diligence on a number of opportunities and working through the process to understand if it’s the right transaction for Cadence. And it’s really valuations are not different than they’ve been, I don’t necessarily see the valuations are going up, but I certainly don’t see them coming down anytime in the near future.
 






Anonymous said:
But wait, there's hope:
YOU ARE PRESENTLY BEING TARGETED!
Theodore R. Schroeder

We’re seeing good strategic opportunities, I think as we’ve discussed before our business development appetitive actually falls into a range of potential transactions everything from a co-promotion, co-marketing agreements to product licensing to acquisition of products. So we have a variety of products in each of those categories where we’re advancing discussions, and there is some or more competitive than others, and I think that’s probably on the acquisitions in the licensing side, that’s probably a bit more competitive than the co-marketing type of arrangements would be, because I think folks tend to actually narrow down on their preferred partners fairly quickly in those scenarios.

so a lot to choose from doing diligence on a number of opportunities and working through the process to understand if it’s the right transaction for Cadence. And it’s really valuations are not different than they’ve been, I don’t necessarily see the valuations are going up, but I certainly don’t see them coming down anytime in the near future.
Click to expand...


Warts are small, usually painless growths on the skin caused by a virus called human papillomavirus (HPV). Most, but not all, are generally harmless. Warts can be disfiguring and embarrassing. Sometimes they itch or hurt ...
 












Anonymous said:
Cadence Pharmaceuticals lost $15.9 million, or 19 cents per share, in the third quarter ended Sept. 30. In the same quarter a year ago, Cadence lost $21.8 million, or 34 cents per share. (The per-share amounts are not comparable, because Cadence issued 21,800 shares in November 2011.)

Cadence reported revenue of $13.9 million for the quarter, compared with $3.5 million in the year-ago quarter. Cadence sells Ofirmev, an intravenous formulation of the painkiller acetaminophen.
Click to expand...

Ouch.
 






Anonymous said:
But wait, there's hope:

Theodore R. Schroeder

We’re seeing good strategic opportunities, I think as we’ve discussed before our business development appetitive actually falls into a range of potential transactions everything from a co-promotion, co-marketing agreements to product licensing to acquisition of products. So we have a variety of products in each of those categories where we’re advancing discussions, and there is some or more competitive than others, and I think that’s probably on the acquisitions in the licensing side, that’s probably a bit more competitive than the co-marketing type of arrangements would be, because I think folks tend to actually narrow down on their preferred partners fairly quickly in those scenarios.

so a lot to choose from doing diligence on a number of opportunities and working through the process to understand if it’s the right transaction for Cadence. And it’s really valuations are not different than they’ve been, I don’t necessarily see the valuations are going up, but I certainly don’t see them coming down anytime in the near future.
Click to expand...

Vintage Schroeder: He talks for hours on end and says absolutely nothing. Loves to hear himself prattle on & on & on. Long on BS, short on facts and stats. Folksy on the outside, arrogantly condescending just below the surface. The ultimate pharma underachieving filibustering politico. The quintessential smoke and mirrors magician who masquerades a rent a rep company as an actual pharmaceutical organization. He could sell ice cubes to Eskimos during the winter solstice.
 






Anonymous said:
Vintage Schroeder: He talks for hours on end and says absolutely nothing. Loves to hear himself prattle on & on & on. Long on BS, short on facts and stats. Folksy on the outside, arrogantly condescending just below the surface. The ultimate pharma underachieving filibustering politico. The quintessential smoke and mirrors magician who masquerades a rent a rep company as an actual pharmaceutical organization. He could sell ice cubes to Eskimos during the winter solstice.
Click to expand...

A little bitter?
 












Top Bottom
Back
Quote